World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
44381
World Ranking
8477
National Ranking
4378

Joseph A. Sparano publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Joseph A. Sparano sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 640 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Joseph A. Sparano D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Joseph A. Sparano sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Joseph A. Sparano is affiliated with Albert Einstein College of Medicine in the United States. Their research focuses primarily on medicine and biochemistry, genetics, and molecular biology, with a notable emphasis on oncology and cancer research.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, their specific subfields of study cover:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Genetics
  • Radiology, Nuclear Medicine and Imaging

Joseph A. Sparano's work extensively addresses the following main topics:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • BRCA gene mutations in cancer
  • Global Cancer Incidence and Screening

Several recent papers show the range and impact of their scholarly contributions. These publications include:

  • Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System, 2020, published in Cancer Discovery
  • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, published in Annals of Oncology
  • Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer, 2022, published in New England Journal of Medicine
  • Seroconversion rates following COVID-19 vaccination among patients with cancer, 2021, published in Cancer Cell
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, published in The Lancet Oncology

The scientist frequently collaborates with colleagues including Lynne I. Wagner, Robert J. Gray, Della Makower, Kathy D. Miller, and Ruth C. Carlos.

Joseph A. Sparano has published numerous articles in prominent journals. The venues where they publish most often are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • npj Breast Cancer
  • Cancer

Best Publications

  • The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    R. Salgado;C. Denkert;S. Demaria;N. Sirtaine

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard

  • Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

    Sylvia Adams;Robert J. Gray;Sandra Demaria;Lori Goldstein

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

    Joseph A. Sparano;Joseph A. Sparano;Molin Wang;Silvana Martino;Vicky Jones

  • Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System

    Clifford A. Hudis;William E. Barlow;Joseph P. Costantino;Robert J. Gray

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.

    Vikas Mehta;Sanjay Goel;Rafi Kabarriti;Daniel Cole

  • Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

    Joseph A. Sparano;Soonmyung Paik

  • A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast

    Lawrence J. Solin;Robert Gray;Robert Gray;Frederick L. Baehner;Steven M. Butler

  • Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010

    Lawrence D. Kaplan;Jeannette Y. Lee;Richard F. Ambinder;Joseph A. Sparano

  • Randomized Controlled Trial of Yoga Among a Multiethnic Sample of Breast Cancer Patients: Effects on Quality of Life

    Alyson B. Moadel;Chirag Shah;Judith Wylie-Rosett;Melanie S. Harris

  • Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

    Joseph A. Sparano;Robert J. Gray;Peter M. Ravdin;Della F. Makower;Della F. Makower

  • Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism

    George S. Karagiannis;Jessica M. Pastoriza;Yarong Wang;Allison S. Harney

  • Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    Sara A. Hurvitz;Miguel Martin;W. Fraser Symmans;Kyung Hae Jung

  • Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

    Lori J. Goldstein;Robert Gray;Sunil Badve;Barrett H. Childs

  • Progress in adjuvant chemotherapy for breast cancer: an overview

    Jesus Anampa;Della Makower;Joseph A. Sparano

Frequent Co-Authors

George W. Sledge
George W. Sledge Stanford University
Nancy E. Davidson
Nancy E. Davidson University of Washington
Kathy D. Miller
Kathy D. Miller Indiana University
Sunil Badve
Sunil Badve Emory University
William C. Wood
William C. Wood Emory University
Jeannette Y. Lee
Jeannette Y. Lee University of Arkansas for Medical Sciences
Edith A. Perez
Edith A. Perez Mayo Clinic
Timothy J. Whelan
Timothy J. Whelan McMaster University
Ronald T. Mitsuyasu
Ronald T. Mitsuyasu University of California, Los Angeles
Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare but seeking alternatives to traditional medical school, there are several respected online degree options and career pathways. Leadership roles in hospitals and clinics are growing, and an online master of health administration can prepare you for high-level administrative positions while allowing flexible study schedules.

Cost is a key concern for many students. Fortunately, there are affordable mha online programs available that help reduce student debt while still providing rigorous training in healthcare policy, management, and leadership.

Nursing professionals looking to advance their clinical expertise may want to consider the cheapest bsn to dnp programs. These Doctor of Nursing Practice programs offer an affordable pathway to becoming a leader in nursing practice or health systems.

Pharmacy is another essential healthcare field that can also be pursued online. A pharmacy degree online provides a flexible option for aspiring pharmacists seeking a career in clinical, research, or community pharmacy settings.

Best Scientists Citing Joseph A. Sparano

Trending Scientists